{"id":1015752,"date":"2026-10-30T08:40:34","date_gmt":"2026-10-30T12:40:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/"},"modified":"2026-10-30T08:40:34","modified_gmt":"2026-10-30T12:40:34","slug":"werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/","title":{"rendered":"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WALTHAM, Mass., Oct.  30, 2026  (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.<\/p>\n<p>\n        <strong>Oral Presentation Details<\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong> A Phase 1\/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed\/refractory, advanced\/metastatic, immunotherapy-sensitive solid tumors<br \/><strong>Abstract<\/strong><strong>Number:<\/strong> 1189<br \/><strong>Presenter: <\/strong>Justin Moser, M.D., HonorHealth Research Institute<br \/><strong>Presentation Time: <\/strong>Saturday, November 7, 2026; 2:30-2:45 p.m. MT<br \/><strong>Location:<\/strong> North Building &#8211; 300 Level \u2013 Halls BC<br \/><strong>Session 205: <\/strong>Clinical Oral Abstract Session 2, 1:30-3:00 p.m. MT<br \/><strong>Session Schedule: <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QwLPX-GKvE6a-tGD1ycbq2SduEZQ2AVY3mlQH2Bq2VxAwItlJaMlrorkV4LxZLQ6ZuxVocwohAiCFSrvQGsfRviW4ZNufenMI_K2o-oKMdWmRm_OgZ8S97IneT9nhlGdFIM0J7tdUezrkOo6SBWg7tCF0-gi7vBf5eyEtN2m2W1-4-v__Z0wzOf1t6hLcDJoQ96rcergjY-3k-QETD2sMhLzcczI25-GvHujOGWXQ48=\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/www.sitcancer.org\/2026\/schedule\/sitc-2026-schedule#session-1643<\/strong><\/a><\/p>\n<p>\n        <strong>Details<\/strong><br \/>\n        <strong>for<\/strong><br \/>\n        <strong>the<\/strong><br \/>\n        <strong>poster<\/strong><br \/>\n        <strong>presentation<\/strong><br \/>\n        <strong> is <\/strong><br \/>\n        <strong>as<\/strong><br \/>\n        <strong>follows:<\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong> A Phase 1b\/2 study of the tumor-activated IL-12 prodrug WTX-330 in patients with relapsed\/refractory solid tumors<br \/><strong>Abstract<\/strong><strong>Number:<\/strong> 494<br \/><strong>Session<\/strong><strong>Date<\/strong><strong>and<\/strong><strong>Time:<\/strong> Saturday, November 7, 2026; 9 a.m.\u20138:30 p.m. MT<br \/><strong>Location:<\/strong> North Building -Lower Level \u2013 Exhibition Halls 4-6<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong>Werewolf<\/strong><br \/>\n        <strong>Therapeutics<\/strong><br \/>\n        <br \/>Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions. Werewolf Therapeutics has designed conditionally activated INDUKINE\u2122 molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf\u2019s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf Therapeutics\u2019 clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for the treatment of solid tumors.<\/p>\n<p>WEREWOLF<sup>\u00ae<\/sup>, the WEREWOLF logo, INDUKINE\u2122 and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.<\/p>\n<p>\n        <strong>Company<\/strong><br \/>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Jonathan Owen<br \/>SVP, General Counsel and Secretary<br \/>Werewolf Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OcMYVKBGnwspNDqikmukFDbd1TMujUDOHghKDUcj-QxPhyboKQu1eEmVkyZURCnMzEI3nfFm-rBz-Tki0rAcDxtNQuNcETmOTa-mstlAs1ftwUoSnbwn_0p6nRYRKO4wP7fsuRT_2whkTM8M22T5DshvMMOfu9bmfg5Ltkx3uE9fr72BPpYUFPhdBgX2h9OKp8v_DMKN1sdxk21ZiDtW9qVVI5XOyXbqCdcof_VumwCxGk4rMc_ZmVsEWWZOTIjk7yDnn_ULhsIv9AMKMvMn5Q==\" rel=\"nofollow\" target=\"_blank\"><strong>jowen@werewolftx.com<\/strong><\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTNiNmE4MTQtMzRjNC00MzY3LTgyNjAtN2E0YWIxOGI2OTc0LTEyMTkzMDAtMjAyNi0xMC0zMC1lbg==\/tiny\/Werewolf-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. Oral Presentation Details Title: A Phase 1\/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed\/refractory, advanced\/metastatic, immunotherapy-sensitive solid tumorsAbstractNumber: 1189Presenter: Justin Moser, M.D., HonorHealth Research InstitutePresentation Time: Saturday, November 7, 2026; 2:30-2:45 p.m. MTLocation: North &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015752","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. Oral Presentation Details Title: A Phase 1\/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed\/refractory, advanced\/metastatic, immunotherapy-sensitive solid tumorsAbstractNumber: 1189Presenter: Justin Moser, M.D., HonorHealth Research InstitutePresentation Time: Saturday, November 7, 2026; 2:30-2:45 p.m. MTLocation: North &hellip; Continue reading &quot;Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-30T12:40:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting\",\"datePublished\":\"2026-10-30T12:40:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/\"},\"wordCount\":367,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/\",\"name\":\"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=\",\"datePublished\":\"2026-10-30T12:40:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting - Market Newsdesk","og_description":"WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. Oral Presentation Details Title: A Phase 1\/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed\/refractory, advanced\/metastatic, immunotherapy-sensitive solid tumorsAbstractNumber: 1189Presenter: Justin Moser, M.D., HonorHealth Research InstitutePresentation Time: Saturday, November 7, 2026; 2:30-2:45 p.m. MTLocation: North &hellip; Continue reading \"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-30T12:40:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting","datePublished":"2026-10-30T12:40:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/"},"wordCount":367,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/","name":"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=","datePublished":"2026-10-30T12:40:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjQ2MCM3OTI1MzMzIzIyMDc3NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-selected-for-oral-presentation-and-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-2026-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015752"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015752\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}